Mesenchymal Stromal Cell Delivery of Oncolytic Immunotherapy Improves CAR-T Cell Anti-tumor Activity

In a paper published in Molecular Therapy, researchers M. McKenna et al. used IsoPlexis’ Functional Proteomics to show that a combination of immuno-stimulatory CAd-MSCs and CAR-T cells improved T cell effector function, endurance, and infiltration into bulky tumors.

Your data is secure

We keep your personal information safe and do not share it with any third parties. By submitting this form, you agree to receive communications from IsoPlexis and accept our Privacy Policy. You may unsubscribe at any time.

What's Inside

In this we discuss:

CAd-MSCs stimulate CAR-T cell cytokine production in vitro
CAd-MSCs promote CAR-T cell-mediated tumor reduction in vivo
Highlighting the importance of a multi-pronged approach for superior therapeutic efficacy
A Deeper Look

More about this

Overcoming Barriers in Adoptive Cell Therapy

The tumor microenvironment (TME) promotes tumor growth and metastasis while suppressing anti-cancer immune responses.

This has proven to be a barrier to adoptive cell therapy. Oncolytic adenoviruses (OAds) can disrupt the TME, thereby restoring and improving immune cell function. However, delivering OAds to solid tumors is challenging.

Researchers from Baylor College of Medicine took a creative approach to this problem by studying how mesenchymal stromal cells (MSCs) can be used to directly deliver two engineered anti-cancer adenoviruses to tumor sites.

Together with CAR-T cell therapy, this approach disrupted the TME, suppressed tumor growth, and encouraged T cell activity.

Download this Paper Summary to see the full findings!

awards-bar-3-wide-color-right
awards-bar-4-wide-color-left
Get the